HOYOUNG HUH, MD, PHD
Hoyung Hug MD, PHD having recently served as a 4DMT Board Member, brings a wealth of expertise on transformational and emerging approaches to biological therapeutics and an extensive scientific and executive leadership background within the biotechnology industry. As former Chairman of Cytomx Therapeutics (NASDAQ:CTMX) and Chairman of Geron Corporation (NASDAQ:GERN), Dr. Huh has been involved in the formation, management and financing of more than 20 successful biotechnology entities across the United States, Europe and Asia.
Dr. Huh was previously the president and CEO of BiPar Sciences Inc., which was acquired by Sanofi-aventis in 2009. He also served as the Chairman of Epizyme Inc. (NASDAQ:EPZM), chief operating officer and board member of Nektar Therapeutics (NASDAQ:NKTR), and board member of Facet Biotech (NASDAQ:FACT), which was acquired by Abbott Laboratories in 2010. Dr. Huh was formerly a partner at McKinsey & Company in the healthcare and technology practices. Dr. Huh holds a AB in biochemistry from Dartmouth College, an MD from Cornell University Medical College, and a PhD in genetics and cell biology from Cornell University/Sloan-Kettering Institute.
D.A. GROS, MD
D.A. Gros has extensive experience in building and financing bio-pharmaceutical companies as well as developing and executing growth strategies. He is the Co-founder and Chief Executive Officer of Imbria Pharmeceuticals and previously served as President, Chief Operating Officer and acting Chief Financial Officer of Neurocrine Biosciences. During his tenure, Neurocrine received FDA approval for and launched Ingrezza®, and completed a $517.5 million financing.
Prior to Neurocrine, D.A. served as Senior Vice President, Chief Business Officer and Principal Financial Officer of Alnylam Pharmaceuticals where his responsibilities included strategy, finance, business development, communications, investor relations, and shared services. Prior to Alnylam, as Executive Vice President and Chief Strategy Officer at Sanofi, D.A.’s responsibilities included corporate strategy, business development and licensing, mergers and acquisitions, alliance management, and structured investments, including the corporate venture fund which he re-launched. Before Sanofi, D.A. held management positions of increasing responsibility with a focus on biotechnology and pharmaceuticals in investment banking at Centerview Partners and Merrill Lynch, and in consulting at McKinsey & Company.
D.A. holds an M.D. from the Johns Hopkins University School of Medicine, an M.B.A. from Harvard Business School, and an A.B. from Dartmouth College.
R.A. SESSION II
Formerly 4DMT’s Chief Business Officer and Head of Corporate Strategy, R.A. was responsible for implementing 4DMT’s corporate strategic goals, driving business development and financing, and managing corporate communications and patient advocacy organization partnerships.
Previously, R.A. was at AveXis where he was Senior Vice President, Corporate Strategy and Business Development. He played a pivotal role in driving the acquisition of AveXis by Novartis for $8.7 Billion dollars. R.A. has extensive leadership experience in Strategy, Corporate Development, New Product Planning, Commercialization and Business Analytics. In addition to his tenure at AveXis, he also held leadership positions at PTC Therapeutics (a rare disease company with DMD/muscle assets), Reata Pharmaceuticals, AstraZeneca, Orbi-McNeal Jansen Pharmaceuticals Services and J&J. R.A. has a M.S. in Finance and M.B.A. from Texas A&M, as well as a B.S. in Business from the University of North Carolina.